Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC93077 in Healthy Subjects and Hyperuricemia Patients
NCT05127772Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC93077 in gout and hyperuricemia (12 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Number of Adverse Events up to 25 days, Area Under the Curve from Time Zero to Infinity up to 18 days and 8 more. Started Nov 2021; status: completed.
02
Drugs
HEC93077
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT05127772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127772.